MedTech Dive April 28, 2023
Q1 Insights
Dexcom, a leading maker of diabetes devices, reported “growing momentum” behind the rollout of its G7 continuous glucose monitor (CGM) system in the first quarter. Progress in the weeks after Dexcom launched the device in February helped the company add more users than in any other quarter in its history.
“Nearly 1,000 health care providers have prescribed G7 who previously were not prescribing Dexcom CGM,” Dexcom CEO Kevin Sayer said on a conference call with investors. “We have advanced coverage more quickly than anticipated, and we expect G7 to be covered by all major [pharmacy benefit managers] by the end of the second quarter.”
Sayer added that Dexcom “already [has] more commercial pharmacy coverage established for G7 today...
Today's Sponsors
Today's Sponsor